

**REMARKS**

Status of the Claims and Preliminary Amendment

The Examiner required Restriction of claims 1-7 and 11-19 in this application. Responsive to the Restriction Requirement, Applicants have canceled claims 1-7 and 14-19 without prejudice to or disclaimer of the subject matter therein (see below). Claims 11-13 are now pending in this application.

Restriction

The Examiner required restriction to one of seven (7) groups. In response to such restriction Applicants wish to proceed as follows.

Applicants elect without traverse Group VII (claims 11-13), drawn to a method of inducing expression of FGF19 in a human hepatocyte cell, for prosecution on the merits and expressly reserves the right to file divisional applications or take such other appropriate measures deemed necessary to protect the inventions in the remaining claims.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,

/Eric J. Kron/

Eric J. Kron  
Attorney for Applicants  
Registration No. 45,941

Date: 15 May 2008  
GlaxoSmithKline  
Five Moore Drive, PO Box 13398  
Research Triangle Park  
North Carolina 27709  
Telephone: (919) 483-8961  
Facsimile: (919) 483-7988